WO2001054771A3 - Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor - Google Patents
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor Download PDFInfo
- Publication number
- WO2001054771A3 WO2001054771A3 PCT/US2001/002743 US0102743W WO0154771A3 WO 2001054771 A3 WO2001054771 A3 WO 2001054771A3 US 0102743 W US0102743 W US 0102743W WO 0154771 A3 WO0154771 A3 WO 0154771A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicant
- potassium channel
- activator
- malignant tumor
- brain region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001234602A AU2001234602A1 (en) | 2000-01-26 | 2001-01-26 | Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor |
EP01906729A EP1251838A2 (en) | 2000-01-26 | 2001-01-26 | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
JP2001554753A JP2003523965A (en) | 2000-01-26 | 2001-01-26 | Methods of using potassium channel agonists to deliver drugs to abnormal brain regions and / or malignancies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/491,500 | 2000-01-26 | ||
US09/491,500 US7018979B1 (en) | 2000-01-26 | 2000-01-26 | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
US61585400A | 2000-07-14 | 2000-07-14 | |
US09/615,854 | 2000-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001054771A2 WO2001054771A2 (en) | 2001-08-02 |
WO2001054771A3 true WO2001054771A3 (en) | 2002-06-20 |
Family
ID=27050462
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/002742 WO2001054680A2 (en) | 2000-01-26 | 2001-01-26 | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
PCT/US2001/002743 WO2001054771A2 (en) | 2000-01-26 | 2001-01-26 | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/002742 WO2001054680A2 (en) | 2000-01-26 | 2001-01-26 | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1251840A2 (en) |
JP (2) | JP2003523965A (en) |
AU (2) | AU2001234602A1 (en) |
WO (2) | WO2001054680A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5022101A (en) | 2000-04-26 | 2001-11-07 | Univ Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cellphenotype |
US7678391B2 (en) | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
GB0021487D0 (en) * | 2000-09-01 | 2000-10-18 | Pfizer Ltd | Pharmaceutical |
US7049334B2 (en) * | 2001-09-14 | 2006-05-23 | Carlsbad Technology, Inc. | Enhancement of learning and memory and treatment of amnesia |
US7211561B2 (en) * | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
JP2005527510A (en) * | 2002-03-06 | 2005-09-15 | セレジー ファーマシューティカルズ インコーポレーティッド | Formulations and methods for using nitric oxide mimetics in the treatment of cancer |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
US20030215889A1 (en) | 2002-03-20 | 2003-11-20 | Simard J. Marc | Non-selective cation channel in neural cells and methods for treating brain swelling |
US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
AU2003240427A1 (en) | 2002-06-26 | 2004-01-19 | Poseidon Pharmaceuticals A/S | Novel benzimidazol-2-one derivatives and their use |
DE10240735A1 (en) * | 2002-08-29 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Regulating human endostatin expression, e.g. for treating CNS disorders or tumors, using nitrogen monoxide signal cascade modulators |
ES2222831B2 (en) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROXIBENCENOSULPHONE COMPOUND AND A K + CHANNEL MODULATOR. |
EP1663239A4 (en) * | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
ES2338022T3 (en) | 2004-06-10 | 2010-05-03 | Nippon Kayaku Kabushiki Kaisha | POTENTIAL OF THE ANTINEOPLASIC EFFECT. |
AU2005290238A1 (en) * | 2004-09-18 | 2006-04-06 | Department Of Veterans Affairs | Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
WO2006091587A2 (en) * | 2005-02-22 | 2006-08-31 | Cedars-Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
JP4119478B1 (en) * | 2005-06-23 | 2008-07-16 | メルク エンド カムパニー インコーポレーテッド | Tyrosine kinase inhibitor |
WO2008089103A2 (en) | 2007-01-12 | 2008-07-24 | University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
AU2009244790B2 (en) * | 2008-05-09 | 2013-09-12 | Duke University | Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
GB0921525D0 (en) * | 2009-12-08 | 2010-01-27 | Isis Innovation | Product and method |
KR102282716B1 (en) * | 2020-02-07 | 2021-07-29 | 포항공과대학교 산학협력단 | Composition for increasing permeability of blood-brain barrier comprising nitric oxide donor and use thereof |
KR102490837B1 (en) | 2020-03-19 | 2023-01-19 | 포항공과대학교 산학협력단 | Method for increasing permeability of blood-brain barrier |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0351767A2 (en) * | 1988-07-18 | 1990-01-24 | E.R. SQUIBB & SONS, INC. | Use of potassium channel activators to inhibit myocardial cell necrosis and to maintain the functioning of the heart during myocardial ischemia and/or reperfusion |
WO1991016355A1 (en) * | 1990-04-23 | 1991-10-31 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability |
EP0555681A1 (en) * | 1992-02-13 | 1993-08-18 | E.R. SQUIBB & SONS, INC. | Use of a combination of potassium channel activators and sulfhydryl containing compounds for the manufacture of a medicament for the treatment of ischemia and myocarolial infarct |
EP0575749A2 (en) * | 1992-06-11 | 1993-12-29 | E.R. SQUIBB & SONS, INC. | Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers |
WO1997031654A1 (en) * | 1996-02-26 | 1997-09-04 | Nicox S.A. | Nitric oxide donors capable of reducing toxicity from drugs |
WO2000023102A1 (en) * | 1998-10-19 | 2000-04-27 | New York University | Method for regulating the permeability of the blood brain barrier |
-
2001
- 2001-01-26 WO PCT/US2001/002742 patent/WO2001054680A2/en active Application Filing
- 2001-01-26 WO PCT/US2001/002743 patent/WO2001054771A2/en active Application Filing
- 2001-01-26 AU AU2001234602A patent/AU2001234602A1/en not_active Abandoned
- 2001-01-26 EP EP01905141A patent/EP1251840A2/en not_active Withdrawn
- 2001-01-26 JP JP2001554753A patent/JP2003523965A/en active Pending
- 2001-01-26 JP JP2001555658A patent/JP2004508279A/en active Pending
- 2001-01-26 AU AU2001233052A patent/AU2001233052A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0351767A2 (en) * | 1988-07-18 | 1990-01-24 | E.R. SQUIBB & SONS, INC. | Use of potassium channel activators to inhibit myocardial cell necrosis and to maintain the functioning of the heart during myocardial ischemia and/or reperfusion |
WO1991016355A1 (en) * | 1990-04-23 | 1991-10-31 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability |
US5112596A (en) * | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
EP0555681A1 (en) * | 1992-02-13 | 1993-08-18 | E.R. SQUIBB & SONS, INC. | Use of a combination of potassium channel activators and sulfhydryl containing compounds for the manufacture of a medicament for the treatment of ischemia and myocarolial infarct |
EP0575749A2 (en) * | 1992-06-11 | 1993-12-29 | E.R. SQUIBB & SONS, INC. | Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers |
WO1997031654A1 (en) * | 1996-02-26 | 1997-09-04 | Nicox S.A. | Nitric oxide donors capable of reducing toxicity from drugs |
WO2000023102A1 (en) * | 1998-10-19 | 2000-04-27 | New York University | Method for regulating the permeability of the blood brain barrier |
Non-Patent Citations (4)
Title |
---|
OAK Z. CHI ET AL: "Effects of Cyclic GMP on Microvascular Permeability of the Cerebral Cortex", MICROVASCULAR RESEARCH, vol. 58, 1999, pages 35 - 40, XP002195899 * |
R. T. BARTUS ET AL: "Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7", EXPERIMENTAL NEUROLOGY, vol. 142, 1996, pages 14 - 28, XP002195901 * |
See also references of EP1251838A2 * |
W. G. MAYHAN: "Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier", BRAIN RESEARCH, vol. 743, 1996, pages 70 - 76, XP002195900 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001054771A2 (en) | 2001-08-02 |
WO2001054680A3 (en) | 2002-06-27 |
AU2001233052A1 (en) | 2001-08-07 |
WO2001054680A2 (en) | 2001-08-02 |
JP2004508279A (en) | 2004-03-18 |
JP2003523965A (en) | 2003-08-12 |
AU2001234602A1 (en) | 2001-08-07 |
EP1251840A2 (en) | 2002-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001054771A3 (en) | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor | |
EP1287830B1 (en) | Use of methioninase as an antitumor agent in anti-methionine chemotherapy | |
WO2003053346A3 (en) | Systems and methods for treating patients with processed lipoaspirate cells | |
CA2413337A1 (en) | Bioadhesive compositions and methods of preparation and use | |
EP0783299A4 (en) | Compounds and compositions for delivering active agents | |
WO2005120407A3 (en) | Preparation for localized delivery of therapeutic agent | |
MXPA05006169A (en) | Compositions and methods of delivery of pharmacological agents. | |
WO2001091728A3 (en) | Nanoemulsion formulations | |
WO2005004895A3 (en) | Compositions and methods for enhanced mucosal delivery of growth hormone | |
WO1996025947A3 (en) | Induction of e-selectin for targetting therapeutic agents | |
AU2624400A (en) | Monodisperse hexameric acylated insulin analog formulations | |
AU8180001A (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells | |
IE882091L (en) | Pharmaceutical compositions comprising sometostatin¹analogues | |
IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
WO2003063780A3 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
ATE156492T1 (en) | BOMB ANALOGUES | |
WO2003033678A3 (en) | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration | |
WO1997042968A3 (en) | Administration of histamine for therapeutic purposes | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
TNSN04235A1 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
NO942919L (en) | Bombesin phenylalanine analogues | |
Nicosia et al. | Effects of vasoactive intestinal polypeptide (VIP) in human prolactin (PRL) secreting pituitary adenomas: Stimulation of PRL release and activation of adenylate cyclase | |
US20090252684A1 (en) | Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of tRNAs for individual amino acids and the protein-bound amino acid profile of the tissue | |
AU3908997A (en) | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors | |
EP0788799A3 (en) | LHRH-Antagonists in the treatment of fertility disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 554753 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001906729 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001906729 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |